Novartis In Line For Ofatumumab MS Approval In June

Will Rival Roche's Ocrevus

 
• By Kevin Grogan

Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.

Calendar_June_2020
Date is in the diary for ofatumumab decision • Source: Shutterstock

More from Neurological

More from Therapy Areas